Managing Dry AMD In Conversation with Dr Anthony Kwan
Available from: 4/05/2026 (AEST)
Available from above date on OA online institute: https://lms.optometry.org.au/course/view.php?id=1006
Provider: Mivision
Contact: Nikki Byrne, [E] nikki@mivision.com.au, [P] 02 8336 8616
Activity Outline
While there
is no established treatment currently available for dry age-related macular
degeneration (AMD), we now have treatments in Australia for geographic atrophy
(GA). Optometrists, as primary eye health providers, play a crucial role in the
diagnosis of patients with these two diseases, providing them with education,
support, and ongoing monitoring under shared care relationships with
ophthalmology.
To prepare
this CPD article, optometrist Tina Huynh interviewed Associate Professor
Anthony Kwan, an academic retinal specialist from the Queensland Eye Institute
in Brisbane, about recognising AMD and early GA on imaging, when and how to
refer for complement inhibitor treatment, and how to explain benefits, risks,
cost, and long-term commitment to patients.
Learning Objectives
- Identify key clinical and imaging signs of dry AMD and GA and know when ophthalmology referral is indicated
- Discuss how intravitreal complement inhibitors work, who benefits most, and what trial data show
- Clearly set expectations, support adherence, and involve patients in shared decisions
- Implement a shared care model for monitoring, co-managing risk factors, coordinating referrals, and supporting vision rehabilitation when needed
Max CPD hours awarded: 1.25
Session Information
| Name |
|---|
| Managing Dry AMD In Conversation with Dr Anthony Kwan |
| Clinical? |
| Yes |
| Interactive? |
| No |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 0.75 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 1.25 |